Takeda Is ‘Now In a Good Phase’ for Growth, CEO Weber Says
- Large acquisition took time to be digested by market
- Entyvio unlikely to face generic rivals until end of decade
This article is for subscribers only.
Takeda Pharmaceutical Co.’s shares might be trading at about half of their level before the $62 billion acquisition of Shire in 2018, but the drug pipeline and cash management are helping to change the market’s perception of the company’s long-term value, Chief Executive Officer Christophe Weber said.
“When you do an acquisition like that of this scale — and it’s not only a big acquisition, it was a very big acquisition compared to our size as well — it’s normal that the market gets a little bit frozen,” Weber, 55, said in an interview. “We are in a different phase, now in a good phase. We are confident about our outlook.”